A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma

References

• Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant 2005;35:215–224.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323–341.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–2502.
   PubMed Web of Science ®Google Scholar
• Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89:717–741.
   PubMed Web of Science ®Google Scholar
• Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs > = 60 years of age. Bone Marrow Transplant 2003;32:1135–1143.
   PubMed Web of Science ®Google Scholar
• Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 2005;16:1801–1805.
   PubMed Web of Science ®Google Scholar
• Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the “Good Study Patient?” Cancer 2009;115:608–615.
   PubMed Web of Science ®Google Scholar
• Martinson BC, Crain AL, Sherwood NE, et al. Population reach and recruitment bias in a maintenance RCT in physically active older adults. J Phys Act Health 2010;7:127–135.
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. Census of Population and Housing 2006 Basic Community Profiles. Available from: www.abs.gov.au
   Google Scholar
• Tracey E, Alam N, Chen W, et al. Cancer in NSW: incidence and mortality 2006. Sydney: Cancer Institute NSW; 2008.
   Google Scholar
• Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007;13:905–912.
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. Australian Standard Geographical Classification (ASGC). ABS Catalogue Number 1216.0. Canberra: ABS; 2009.
   Google Scholar
• Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006;107:397–403.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–793.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55–65.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158–164.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131–3136.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–9233.
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Cameron K. Cancer and cancer risk in South Australia: what evidence for a rural-urban health differential? Aust J Rural Health 2004;12:61–66.
   PubMedGoogle Scholar
• Jong KE, Smith DP, Yu XQ, et al. Remoteness of residence and survival from cancer in New South Wales. Med J Aust 2004;180:618–622.
   PubMed Web of Science ®Google Scholar
• Paulson K, Lambert P, Bredeson C, et al. Does location matter? Rural vs urban outcomes after blood and marrow transplantation in a population-based Canadian cohort. Bone Marrow Transplant 2010;45:1167–1173.
   PubMed Web of Science ®Google Scholar
• Rao K, Darrington DL, Schumacher JJ, et al. Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence. Biol Blood Marrow Transplant 2007;13:1508–1514.
   PubMed Web of Science ®Google Scholar
• Loberiza FR, Lee SJ, Klein JP, et al. Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence. Biol Blood Marrow Transplant 2010;16:368–375.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51–54.
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjorth M, Westin J, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389–396.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993–1999.
   PubMed Web of Science ®Google Scholar
• Barlogie B, van Rhee F, Shaughnessy JD Jr, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112:3122–3125.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011;71:625–649.
   PubMed Web of Science ®Google Scholar
• Satoh M, Oguro R, Yamanaka C, et al. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. J Pharm Pharm Sci 2011;14:78–89.
   PubMed Web of Science ®Google Scholar